作者: Mao, Na ; Zhang, Chuanxi ; Liu, Heliang ; Xu, Hong ; Yang, Jie ; Zheng, Ruiping ; Jin, Hui ; Cai, Wenchen ; Gao, Xuemin ; Zhang, Ziyan ; Wu, Yiling ; Kang, Yumeng

AbstractRosacea is a chronic inflammatory skin disorder that can lead to fibrosis. However, the mechanisms underlying fibrosis in the later stages of rosacea have been less thoroughly investigated. Interleukin‐17A (IL‐17A) has been implicated in both inflammation and organ fibrosis; however, the effectiveness and mechanism of IL‐17A‐neutralizing antibodies in the later stages of rosacea‐related fibrosis remain unclear. In this study, we induced rosacea‐like lesions in mice using LL‐37 and administered IL‐17A‐neutralizing antibodies. The results indicated that the IL‐17A‐neutralizing antibodies alleviated skin damage, reduced skin thickness, and decreased the secretion of inflammatory factors (TNF‐α, CAMP, TLR4, P‐NF‐kB), angiogenesis‐related factors (CD31, VEGF), and the TGF‐β1 signaling pathway, along with factors associated with epithelial–mesenchymal transition and the deposition of fibrosis‐related proteins (COL1) in the rosacea‐like mouse models. Furthermore, the IL‐17A‐neutralizing antibodies effectively diminished the expression of IL‐17, IL‐17R, CXCL5, and CXCR2 in the skin. Our findings demonstrate that IL‐17A‐neutralizing antibodies inhibit the activation of the CXCL5/CXCR2 axis in rosacea‐like skin tissue, thereby ameliorating inflammation and fibrosis associated with the condition.

2024-10-01·International Journal of Biological Macromolecules

LL-37 and bisphosphonate co-delivery 3D-scaffold with antimicrobial and antiresorptive activities for bone regeneration

Article

作者: Limjunyawong, Nathachit ; Yang, Wenxin ; Zhang, Zehua ; Zhao, Weikang ; Zhang, Jie ; Guo, Shuquan ; Zhang, Chengmin ; Yang, Yusheng ; Sun, Dong ; Xu, Jianzhong ; Song, Lei ; Luo, Fei ; Tang, Yong ; Dou, Ce ; Ye, Peng ; Qu, Ying ; Hou, Tianyong ; Tan, Jiulin ; Dong, Shiwu

This study introduces a novel 3D scaffold for bone regeneration, composed of silk fibroin, chitosan, nano-hydroxyapatite, LL-37 antimicrobial peptide, and pamidronate. The scaffold addresses a critical need in bone tissue engineering by simultaneously combating bone infections and promoting bone growth. LL-37 was incorporated for its broad-spectrum antimicrobial properties, while pamidronate was included to inhibit bone resorption. The scaffold's porous structure, essential for cell infiltration and nutrient diffusion, was achieved through a freeze-drying process. In vitro assessments using SEM and FTIR confirmed the scaffold's morphology and chemical integrity. Antimicrobial efficacy was tested against pathogens of Staphylococcus aureus (S. aureus) and Pseudomonas aeruginosa (P. aeruginosa). In vivo studies in a murine model of infectious bone defect revealed the scaffold's effectiveness in reducing inflammation and bacterial load, and promoting bone regeneration. RNA sequencing of treated specimens provided insights into the molecular mechanisms underlying these observations, revealing significant gene expression changes related to bone healing and immune response modulation. The results indicate that the scaffold effectively inhibits bacterial growth and supports bone cell functions, making it a promising candidate for treating infectious bone defects. Future studies should focus on optimizing the release of therapeutic agents and evaluating the scaffold's clinical potential.

2024-09-14·Molecules (Basel, Switzerland)

Thermodynamic Study on Biomimetic Legionella gormanii Bacterial Membranes.

Article

作者: Wiącek, Agnieszka Ewa ; Palusińska-Szysz, Marta ; Pastuszak, Katarzyna ; Jurak, Małgorzata

The presented studies were aimed at determining the interactions in model membranes (Langmuir monolayers) created of phospholipids (PL) isolated from Legionella gormanii bacteria cultured with (PL + choline) or without (PL - choline) choline and to describe the impact of an antimicrobial peptide, human cathelicidin LL-37, on PL's monolayer behavior. The addition of choline to the growth medium influenced the mutual proportions of phospholipids extracted from L. gormanii. Four classes of phospholipids-phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylglycerol (PG), cardiolipin (CL), and their mixtures-were used to register compression isotherms with or without the LL-37 peptide in the subphase. Based on them the excess area (Ae), excess (ΔGe), and total (ΔGm) Gibbs energy of mixing were determined. The thermodynamic analyses revealed that the PL - choline monolayer showed greater repulsive forces between molecules in comparison to the ideal system, while the PL + choline monolayer was characterized by greater attraction. The LL-37 peptide affected the strength of interactions between phospholipids' molecules and reduced the monolayers stability. Accordingly, the changes in interactions in the model membranes allowed us to determine the difference in their susceptibility to the LL-37 peptide depending on the choline supplementation of bacterial culture.

项与 prLL-37 相关的新闻（医药）

2023-09-07

·PRNewswire

United Imaging Confirms Installation of Country's First uMI Panorama™ at Huntsman Cancer Institute

The award-winning 12-year old manufacturer and widely-recognized leading cancer center agreed to install United Imaging's recently unveiled innovation. HOUSTON, Texas, Sept. 7, 2023 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, announced that The Center for Quantitative Cancer Imaging (CQCI) at Huntsman Cancer Institute, part of the University of Utah health care system in Salt Lake City, has installed another United Imaging PET/CT scanner. This brings state-of-the-art molecular imaging technology to the CQCI clinical research lab. Huntsman Cancer Institute is designated as a Comprehensive Cancer Center by the National Cancer Institute (NCI). The new uMI Panorama features a 2.9 mm NEMA resolution, 35 cm axial FOV and 194 ps timing resolution and was unveiled at SNMMI's annual meeting in Chicago. According to Jeffrey Yap, Ph.D, Director of the Center for Quantitative Cancer Imaging (CQCI) at Huntsman Cancer Institute and Research Professor in the Department of Radiology and Imaging Sciences at the University of Utah, "We are always striving for ways to bring the best technology and highest level of cancer care to our patients. We believe this new scanner will provide better image quality and improve patient comfort. Delivering world-class cancer treatment to our patients is our highest priority." The uMI Panorama was cleared by the FDA in March 2023; Huntsman Cancer Institute is the first to install this groundbreaking technology in the entire United States. In 2022, Huntsman Cancer Institute announced installation of the first United Imaging uMI 780 PET/CT system in North America. "The first of anything is always exciting, especially when it is so unique and will be put to good use by the experts at Huntsman Cancer Institute," commented Jeffrey M. Bundy, Ph.D, CEO of United Imaging Healthcare Solutions. ABOUT UNITED IMAGING At United Imaging, we develop and manufacture advanced medical products, digital healthcare solutions, and intelligent solutions that cover the entire process of imaging diagnosis and treatment. Founded in 2011, our company has subsidiaries and R&D centers across the world. Our North American headquarters in Houston includes our corporate offices, factory, product showroom, service training center, and service parts distribution center. With a cutting-edge digital portfolio and a mission of Equal Healthcare for All™, we help drive industry progress and bold change. To learn more, visit united-imaging.com or follow us on LinkedIn and Twitter @UnitedImagingHC. SOURCE United Imaging Healthcare Co., Ltd.

2023-06-25

·PRNewswire

United Imaging Introduces Next-Generation PET/CT Systems and Integrated Molecular Technology Platform at SNMMI

With uMI Panorama™, United Imaging Continues to Push the Envelope on Whole-Body System Performance HOUSTON, June 25, 2023 /PRNewswire/ -- United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment and a Leadership Circle sponsor at this year's SNMMI, is making news on several fronts at SNMMI's annual meeting in Chicago this week. "There has been a debate in the marketplace for a while about the relative importance of resolution, axial field of view (FOV), and time of flight (TOF)," said Jeffrey Bundy, Ph.D, CEO of United Imaging Healthcare Solutions about the company's product launch. "With the new wide-bore uMI Panorama and its 2.9 mm NEMA resolution, 35 cm axial FOV and 194 ps timing resolution, we will gladly have a conversation on any single specification or the collective benefit of all of them, because with this particular product, the need to compromise is gone." The uMI Panorama was teased recently in the media as one of United Imaging's four new products in four different imaging modalities so far this year. Cheri Gottke, Vice President of the Molecular Imaging portfolio for the U.S., added that the uMI Panorama is currently installed at Huntsman Cancer Center in Salt Lake City, Utah and that "we chose SNMMI as the official stage to debut it." United Imaging is showcasing a cutting-edge Molecular Imaging technology platform along with the uMI Panorama, called uExcel. The platform integrates hardware and software innovations to optimize performance, imaging capabilities and system functionalities. Its ultra-digital platform (UDP) detector boasts a high-performance ASIC chip, and its AI-empowered workflow streamlines operations and enhances examination efficiency. Exceptional image quality can be achieved with a lower dose, and the quality assurance module maintains peak performance of the system. The uMI Panorama is a family of products that also includes a 510k pending system with a 148 cm axial FOV, the uMI Panorama GS. Built on the uExcel platform, this ultra-long axial FOV system allows for fast and high-resolution whole-body PET/CT imaging in a single bed position. The uMI Panorama GS is also being unveiled at SNMMI. United Imaging continues to see steady acceleration in demand for its popular digital PET/CT the uMI® 550, in both mobile and fixed configurations. "This is one of our most important molecular imaging innovations," continued Gottke. "The entire digital portfolio from the uMI 550 to the uMI Panorama offers exceptional PET and CT image quality that improves quantitative accuracy and small lesion detectability. Our portfolio includes All-In Configurations™ and Software Upgrades for Life™ so that all our scanners truly stand the test of time from both a technological and a clinical perspective." The entire uMI portfolio is also "Born with AI" from the ground up, rather than being retrofitted with it later. This allows a seamless integration of artificial intelligence (AI) across all products, which optimizes daily workflow, improves the patient experience, and creates stunning diagnostic images. United Imaging's artificial intelligence (uAI®) streamlines routine clinical workflows by auto iso-centering patients and defining the scan range. Its systems also allow faster scanning with less dose, while improving PET and CT imaging quality and providing image consistency in all clinical settings, from academic to freestanding imaging centers. SNMMI announced in its Value Initiative Newsletter that United Imaging is joining the Leadership Circle and taking an Industry co-chair position. United Imaging this week is also hosting two Satellite Symposiums (available for registration on the SNMMI meeting website) and a by-invitation-only customer event: uEXPLORER Symposium on June 25: "Exploring the Unmatched Capabilities of Total Body Imaging: Reflections on 5 Years of Clinical Adoption"; presenters include Dr. Ramsey Badawi, Vice Chair for Research, Department of Radiology, University of California, Davis and Dr. Harshad Kulkarni, Chief Medical Advisor, BAMF Health. uMI Panorama Symposium on June 26: "Advancing Precision Medicine with Unprecedented PET/CT Technology for Clinical Molecular Imaging" on Monday, June 26, from 11:30 am – 12:30 pm. Presenters include Dr. Jeffrey Yap, Director, Center for Quantitative Imaging at Huntsman Cancer Institute. United Imaging Educational Evening "UIH Night" (Invitation Only), Sunday June 25th. Presenters include Dr. Richard Carson, Professor of Biomedical Engineering and Radiology, Yale University and Dr. Simon Cherry, Professor of Biomedical Engineering and Radiology, UC Davis United Imaging is located at booth #4032. ABOUT UNITED IMAGING At United Imaging, we develop and manufacture advanced medical products, digital healthcare solutions, and intelligent solutions that cover the entire process of imaging diagnosis and treatment. Founded in 2011, our company has subsidiaries and R&D centers across the world. Our North American headquarters in Houston includes our corporate offices, factory, product showroom, service training center, and service parts distribution center. With a cutting-edge digital portfolio and a mission of Equal Healthcare for All™, we help drive industry progress and bold change. To learn more, visit united-imaging.com or follow us on LinkedIn and Twitter @UnitedImagingHC. SOURCE United Imaging Healthcare Co., Ltd.

100 项与 prLL-37 相关的药物交易

登录后查看更多信息